Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort

Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort

Introduction: Lumasiran is a drug used in RNA-interference (RNAi) therapy for primary hyperoxaluria type 1 (PH1). Data on its efficacy and safety mainly come from industry-sponsored trials. Methods: For postmarketing follow-up, French authorities requested a quasi-exhaustive retrospective and prospe...

Full description

Saved in:
Bibliographic Details
Main Authors: Anne-Laure Sellier-Leclerc, Melissa Cloarec, Bertrand Knebelmann, Lise Allard, Olivia Boyer, Sylvie Cloarec, Claire Dossier, Moglie Le Quintrec, François Nobili, Thomas Stehlé, Isabelle Vrillon, Stéphane Burtey, Emilie Cornec-Le Gall, Marie Courbebaisse, Thierry Frouget, Arnaud Garnier, Thierry Krummel, Sandrine Lemoine, Catherine Monet-Didailler, Caroline Rousset-Rouvière, Amélie Ryckewaert, Adeline Schendel, Sacha Flammier, Cécile Acquaviva-Bourdain, Justine Bacchetta
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Kidney International Reports
Subjects:
dialysis
hyperoxaluria type 1
lumasiran
real-life data
RNA interference
transplantation
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492403482X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S246802492403482X

Similar Items